Ascendis’ TransCon Positioned To Take On BioMarin’s Voxzogo

The Danish company released pivotal data for TransCon CNP in children with achondroplasia that appears competitive with BioMarin’s big growth driver.

Ascendis announced positive Phase III data that hit the mark with investors • Source: Shutterstock

Ascendis Pharma A/S is preparing to file a new drug application for TransCon CNP (navepegritide) early next year for treatment of the growth condition achondroplasia after announcing positive results from the Phase III ApproaCH trial on 16 September.

TransCon CNP is intended to rival to BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide), which was granted accelerated approval by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.